title: Ensuring safety of biosimilar low-molecular-weight heparins: a consensus statement of the International Union of Angiology .
authors.forename: J
authors.initials: J
authors.lastname: Harenberg
authors.forename: E
authors.initials: E
authors.lastname: Kalodiki
authors.forename: J M
authors.initials: JM
authors.lastname: Walenga
mesh_terms: D000818:Animals; D000925:Anticoagulants / Q000009:adverse effects / Q000592:standards* / Q000627:therapeutic use*; D059451:Biosimilar Pharmaceuticals / Q000009:adverse effects / Q000592:standards*; D001777:Blood Coagulation / Q000187:drug effects*; D016568:Drugs, Generic / Q000009:adverse effects / Q000592:standards* / Q000627:therapeutic use*; D006470:Hemorrhage / Q000139:chemically induced; D006495:Heparin, Low-Molecular-Weight / Q000009:adverse effects / Q000592:standards* / Q000627:therapeutic use*; D006801:Humans; D061214:Patient Safety / Q000592:standards*; D018570:Risk Assessment; D012307:Risk Factors
chemical_list: D000925:Anticoagulants; D059451:Biosimilar Pharmaceuticals; D016568:Drugs, Generic; D006495:Heparin, Low-Molecular-Weight